熱門資訊> 正文
Enveric股价因放射性皮炎药物交易上涨7%
2024-07-15 22:24
- Shares of Enveric Biosciences (NASDAQ:ENVB) rose 7% Monday morning after the company announced it had entered into a licensing deal with encapsulation technology developer Aries Science & Technology for the development and commercialization of Enveric’s topical radiation dermatitis product.
- Under the deal, Enveric will be eligible to receive milestone payments of up to $61 million, plus tiered royalties ranging from 2.5% to 10% on future sales. The product is being developed for the treatment of skin irritation associated with radiation therapy.
- The agreement was executed through Enveric’s Akos Biosciences unit. The product will be developed through a newly formed Aries subsidiary, according to a statement.
More on Enveric Biosciences
- Enveric Biosciences signs $66.5M non-binding term sheet with MindBio Therapeutics
- Seeking Alpha’s Quant Rating on Enveric Biosciences
- Historical earnings data for Enveric Biosciences
- Financial information for Enveric Biosciences
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
